OMCL

OMCL

OMCL

Letters With This Ticker

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Keywords/Themes	Theme Commentary	Pitches	Letter
2024 Q2	Sep 5, 2024	Brown Capital Management Mid Company Fund	-7.9%	-3.1%	ALGN, CRL, FIVN, GWRE, NTRA, OMCL, PAYC, PODD, TDOC, VEEV	Biotechnology, growth, healthcare, Medical Devices, mid cap, software, technology	Charles River Laboratories, a pre-clinical contract research organization involved in 80% of FDA-approved drugs, is experiencing significant headwinds from higher interest rates curtailing capital market funding for biotech customers. Small and medium-sized biotech companies represent 40% of Charles River's client base and are most affected by the weaker funding environment, leading to consecutive quarterly revenue declines for the first time since 2008-2009. The manager believes this represents the worst capital-raising environment for biotech in at least five years.	NTRA FIVN CRL PODD GWRE	View
2024 Q1	Apr 23, 2024	ClearBridge Investments Small Cap Growth Strategy	0.0%	0.0%	CNMD, DOOR, DUOL, ELF, FWRD, IART, INSM, INTA, IRDM, MEDP, MSTR, OC, OMCL, RDNT, SMCI, TMO, TREX, VKTX, WING, XPO	AI, Biotechnology, growth, healthcare, small cap, technology	AI infrastructure build-out has had a narrow set of beneficiaries, with enthusiasm for AI fueling atypical concentration and performance distortion in the benchmark. RadNet has invested heavily in newer AI applications that can provide an additional revenue stream while improving early identification of cancers.	ELF DUOL INTA INSM MEDP RDNT CNMD VKTX	View
2023 Q3	Sep 30, 2023	Conestoga Small Cap Composite	10.1%	7.8%	ALTR, AZTA, CSWI, CWAN, CWST, DGII, FICO, HLIO, MLAB, MODN, NOVT, NRC, OMCL, PRO, RGEN, ROAD, SPSC, SSD, TRNS, VERX	growth, healthcare, industrials, Quality, small cap, technology	Conestoga emphasizes profitable companies with lower debt levels relative to benchmarks, which they believe positions their strategies for outperformance in an economy facing higher interest rates and potential recession. Higher-quality companies enjoyed stronger relative performance in the third quarter.		View
2023 Q3	Sep 30, 2023	Conestoga SMid Cap Composite	12.9%	12.1%	CSWI, CWAN, CWST, DSGX, EXPO, FICO, FSV, GGG, GWRE, MMSI, NOVT, OMCL, POOL, RGEN, ROAD, ROL, SPSC, WSO	growth, healthcare, infrastructure, Quality, small cap, technology	Conestoga emphasizes higher-quality companies with positive earnings, higher margins, higher returns on equity, and lower debt levels. This quality focus positioned their strategies for outperformance in an environment facing higher interest rates and potential recession.	NSTG AD8 AU\|ARB AU\|BAP AU\|CAT AU\|DHG AU\|PME AU\|PNI AU\|RDX AU\|TNE AU OMCL CSWI	View
2023 Q3	Aug 10, 2023	ClearBridge Investments Small Cap Growth Strategy	0.0%	0.0%	AEL, ALGM, BJ, CASY, FWRD, HUBS, IRDM, KVYO, LNTH, MGRC, MOG.A, NCNO, NEWR, NMIH, NOVT, ODD, OMCL, PEN, PODD, SGFY, SHOP, SYNH, WHD, XPO	Banking, growth, healthcare, Medical Devices, small caps, software, technology	The early August revelation that GLP-1 diabetes and obesity treatment semaglutide has potentially important cardiovascular benefits led to pervasive selling across medical technology stocks. While longer-term implications were most pointed for diabetes stocks, reverberations were felt across cardiovascular, orthopedic and surgery-related stocks.	LNTH MGRC NCNO KVYO	View
2022 Q4	Jan 31, 2023	Meridian Small Cap Growth Fund	6.2%	0.0%	DICE, HDSN, OMCL, SYNH, TIL	-			View
2023 Q4	Jan 16, 2024	Brown Capital Management Mid Company Fund	-7.9%	-3.1%	DXCM, MANH, OMCL, SHOP.TO, VEEV	E-Commerce, growth, healthcare, Medical Devices, mid cap, software, Supply Chain, technology	Clinical trial results showed GLP-1 obesity drugs lower diabetes and cardiovascular disease risk, initially causing investor fears about medical device companies. However, additional studies revealed high patient discontinuation rates, alleviating concerns and supporting coexistence with other therapies like continuous glucose monitors.	VEEV OMCL MANH SHOP DXCM	View

Pitches With This Ticker

Date	Pitch Type	Author	Company	Industry	Sub Industry	Bull / Bear	Stock Exchange	Keywords	Action
Apr 28, 2026	Fund Letters	Conestoga Mid Cap Composite	Omnicell, Inc.	Health Care	Health Care Technology	Bear	NASDAQ	business transformation, Hardware to Software, Healthcare Technology, Hospital Spending, margin pressure, Medication Management, recurring revenue, Revenue Mix	View Pitch
Apr 28, 2026	Fund Letters	Conestoga SMid Cap Composite	Omnicell, Inc.	Health Care	Health Care Technology	Bear	NASDAQ	business transformation, Healthcare Technology, Hospital Spending, Medication Management, recurring revenue, Software Transition	View Pitch
Apr 28, 2026	Fund Letters	Brown Capital Management Mid Company Fund	Omnicell	Health Care Equipment & Services	Health Care Equipment	Bull	NASDAQ	cash flow positive, cost savings, Cyclical Recovery, Healthcare Technology, Hospital Automation, Medication Management, Pharmacy Robotics	View Pitch

BSD Shareholders of OMCL

This report provides a detailed summary of investor holdings for a specified stock ticker, highlighting key metrics such as fund name, total assets under management (AUM), invested value, portfolio weight, and shares owned. It also tracks changes in share ownership during the last quarter, including the percentage of shares bought or sold and the percentage of outstanding shares owned. The data is generated using an API that processes investor holdings and calculates these values for each fund. This report helps investors and analysts monitor the stock positions of major funds, identify investment trends, and assess the influence of large investors on individual stocks.

Filing Date: September 30, 2025

Manager Name	Fund Name	Fund AUM	Invested Value	Portfolio Weight	Shares Owned	Shares Bought / Sold During Quarter	% Bought / Sold During Quarter	% of Shares Outstanding Owned
No investor data available.

Join for free and get access to the buyside

Get insights from the world's most influential hedge fund investors direct to your inbox

Follow Us On: